Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, November 13, 2014
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), announced today that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX 2-73, as ...
read more
Monday, February 09, 2015
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015...
read more
Thursday, December 18, 2014
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of ...
read more
Monday, November 17, 2014
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS), and various types of ...
read more
Anbio, a leading provider of innovative diagnostic Solutions, presents the Anbio LAMP Solution, an innovative point-of-care Solution designed for easy-to-use but elegantly sophisticated qualitative diagnostics.
read more
Ancor Capital Partners, a Dallas private equity firm, has announced the sale of WellSpring Pharma Services to ANI Pharmaceuticals.
read more
Andelyn Biosciences and ENCell announced the signing of a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to accelerate the global delivery of gene therapies.
read more
Andelyn Biosciences, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/...
read more
Andelyn Biosciences, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Purespring Therapeutics, a biotech company, to accelerate the manufacture of their gene therapies for the treatment of ...
read more
Wednesday, September 03, 2025
Andelyn Biosciences has partnered with Tern Therapeutics to perform late-stage Process Performance Qualification (PPQ) manufacturing of Tern's TTX-381 program. TTX-381 is an investigational gene therapy targeting vision loss in children with CLN2 ...
read more
Thursday, November 09, 2023
Andelyn Biosciences, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), is collaborating with The Ohio State University Gene Therapy Institute for the development and clinical manufacturing of novel gene ...
read more
Wednesday, August 07, 2024
Andelyn Biosciences, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has entered into a License Agreement with the Broad Institute to expand its AAV Curator™ Platform offering to include MyoAAV plasmids.
read more
Andelyn Biosciences has manufactured a viral vector with its AAV Curator® Platform for the Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program. The Adeno-Associated Virus (AAV) will be utilized in a novel cell therapy for ...
read more
Andelyn Biosciences, a developer and manufacturer of cell and gene therapies, opened its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.
read more
Andelyn Biosciences announced a partnership with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies (LGMDs).
read more